Class Action Claims Arising from Drug Shortage Untimely, 1st Cir. Rules
February 29, 2024
DOCUMENTS
- Opinion
BOSTON — Certain class action claims alleging injuries caused by Genzyme Corp.’s alleged mishandling of a drug shortage between 2009 and 2012 are time barred because they were not revived by a tolling agreement between the parties, the 1st Circuit U.S. Court of Appeals has ruled.
In a Feb. 16 opinion, the appellate panel explained that because the claims expired long before the tolling agreement was signed, they do not survive Genzyme's statute-of-limitations defense.
From 2003 until 2009, Genzyme steadily provided Fabrazyme, which is used to treat Fabry disease — a disorder that causes buildup of a certain fat substance …
UPCOMING CONFERENCES
![](https://harrismartin.s3.amazonaws.com/media/CACHE/images/uploads/conferences/iStock-1191161494_wqZG9UX/0b903ab949806641ed5433861fdab9cd.jpg)
HarrisMartin's Data Breach Litigation Conference
September 25, 2024 - Nashville, TN
Hutton Hotel in Lyric Ballroom C